Cargando…

Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report

The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the se...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Hironobu, Itoh, Arata, Watanabe, Yasuhiro, Nakajima, Yuya, Saisho, Yoshifumi, Irie, Junichiro, Meguro, Shu, Itoh, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153841/
https://www.ncbi.nlm.nih.gov/pubmed/35088548
http://dx.doi.org/10.1111/jdi.13757
_version_ 1784717920504381440
author Sasaki, Hironobu
Itoh, Arata
Watanabe, Yasuhiro
Nakajima, Yuya
Saisho, Yoshifumi
Irie, Junichiro
Meguro, Shu
Itoh, Hiroshi
author_facet Sasaki, Hironobu
Itoh, Arata
Watanabe, Yasuhiro
Nakajima, Yuya
Saisho, Yoshifumi
Irie, Junichiro
Meguro, Shu
Itoh, Hiroshi
author_sort Sasaki, Hironobu
collection PubMed
description The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new‐onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease‐susceptible human leukocyte antigen haplotype, DRB1*04:05:01‐DQB1*04:01:01. The glucagon stimulation test suggested an insulin‐dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID‐19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β‐cells associated with the vaccination. In recipients with the disease‐susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination.
format Online
Article
Text
id pubmed-9153841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91538412022-06-05 Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report Sasaki, Hironobu Itoh, Arata Watanabe, Yasuhiro Nakajima, Yuya Saisho, Yoshifumi Irie, Junichiro Meguro, Shu Itoh, Hiroshi J Diabetes Investig Articles The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new‐onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease‐susceptible human leukocyte antigen haplotype, DRB1*04:05:01‐DQB1*04:01:01. The glucagon stimulation test suggested an insulin‐dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID‐19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β‐cells associated with the vaccination. In recipients with the disease‐susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination. John Wiley and Sons Inc. 2022-02-11 2022-06 /pmc/articles/PMC9153841/ /pubmed/35088548 http://dx.doi.org/10.1111/jdi.13757 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Sasaki, Hironobu
Itoh, Arata
Watanabe, Yasuhiro
Nakajima, Yuya
Saisho, Yoshifumi
Irie, Junichiro
Meguro, Shu
Itoh, Hiroshi
Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
title Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
title_full Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
title_fullStr Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
title_full_unstemmed Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
title_short Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
title_sort newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153841/
https://www.ncbi.nlm.nih.gov/pubmed/35088548
http://dx.doi.org/10.1111/jdi.13757
work_keys_str_mv AT sasakihironobu newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT itoharata newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT watanabeyasuhiro newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT nakajimayuya newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT saishoyoshifumi newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT iriejunichiro newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT meguroshu newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport
AT itohhiroshi newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport